Pharmacy Times will be covering the 2023 San Antonio Breast Cancer Symposium (SABCS), happening December 5 through 9 in Texas.
This year’s meeting will provide state-of-the-art updates and information on diagnosis, prevention, and therapeutic advances in breast cancer. The program includes expert lectures, forums, and case discussions, as well as poster presentations. Pharmacy Times will also feature exclusive interviews with presenters.
Image credit: SciePro | stock.adobe.com
Stay tuned on PharmacyTimes.com for session coverage and interviews, including:
- On Tuesday, December 5, Special Session 1 will cover new drug approvals in metastatic breast cancer, including elecastrant, trastuzumab deruxtecan, and new drugs currently under review. Presenters and panelists in this session include FDA experts and clinicians from across the country.
- A conversation with Douglas B. Johnson, MD, MSCI, leader of the melanoma clinical research program at Vanderbilt. Johnson will be discussing short- and long-term toxicity management with immunotherapies, including key considerations for monitoring, strategies for pharmacists to educate and counsel patients on toxicities, and specific interventions or prophylactic measures.
- On Wednesday, December 6, an educational session will feature updates from the clinic and the lab settings on HER2-positive breast cancer. This includes reviews of molecular determinates of response and resistance, advances in systemic disease, and novel systemic therapy strategies for brain metastases.
- An interview with Amelie G. Ramirez, DrPh, MPH, about the impacts of social determinants of health (SDOH) on cancer care. In particular, Ramirez will review key SDOH that impact cancer care outcomes, the impacts of cost on access to necessary treatments, and how health care providers can better advocate for their patients.
- On Friday, December 8, Plenary Lecture 2 will discuss recent advances in triple negative breast cancer, with moderator Virginia Kaklamani, MD, of UT Health San Antonio, and presenter Melinda L. Telli, MD, of the Stanford University School of Medicine.
- A conversation with Mara Hofherr, PharmD, RPh, about a poster comparing Black and White patients with triple-negative breast cancer who were receiving therapy in the KEYNOTE-522 study. Hofherr will discuss key findings in the research, the ways that demographics and socioeconomic factors contribute to disparities in care, and how pharmacists can collaborate with health care teams to ensure patient-centered, culturally competent care.
Stay tuned on PharmacyTimes.com and on our social media channels for all of these and more from 2023 SABCS.